BODY MASS INDEX AND BEVACIZUMAB IN FIRST LINE TREATMENT FOR ADVANCED OVARIAN CANCER (AOC)

Mapping Intimacies ◽

10.26226/morressier.5770e29cd462b80290b4c076 ◽

2016 ◽

Author(s):

Ida Paris

Keyword(s):

Ovarian Cancer ◽

Body Mass Index ◽

Body Mass ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour I'Etude des Cancers Ovariens

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70319-1 ◽

2007 ◽

Vol 2007 ◽

pp. 69-70

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Study Group ◽

Line Treatment ◽

Cancer Study ◽

Cancer Study Group ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.01.194 ◽

2015 ◽

Vol 137 ◽

pp. 79

Author(s):

N.D. Fleming ◽

R.L. Coleman ◽

C.S. Tung ◽

M.F. Munsell ◽

A.K. Sood

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line Treatment

Download Full-text

First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer

Gynecologic Oncology ◽

10.1016/s0090-8258(03)00472-4 ◽

2003 ◽

Vol 90 (3) ◽

pp. S8-S15 ◽

Author(s):

Gavin C.E Stuart

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Consolidation Therapy ◽

Line Treatment ◽

Treatment Regimens ◽

First Line Treatment

Download Full-text

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG

Annals of Oncology ◽

10.1093/annonc/mds060 ◽

2012 ◽

Vol 23 (10) ◽

pp. 2613-2619 ◽

Author(s):

K. Lindemann ◽

R.D. Christensen ◽

I. Vergote ◽

G. Stuart ◽

M.A. Izquierdo ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.lba5007 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. LBA5007-LBA5007 ◽

Author(s):

J. Pfisterer ◽

B. Weber ◽

A. Du Bois ◽

A. Lortholary ◽

C. Schade-Brittinger ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djj296 ◽

2006 ◽

Vol 98 (15) ◽

pp. 1036-1045 ◽

Author(s):

Jacobus Pfisterer ◽

Béatrice Weber ◽

Alexander Reuss ◽

Rainer Kimmig ◽

Andreas du Bois ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text

Sequential gemcitabine–carboplatin followed by paclitaxel–carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.043 ◽

2006 ◽

Vol 101 (1) ◽

pp. 114-119 ◽

Author(s):

Johanna U. Mäenpää ◽

Seija E. Grénman ◽

Jyrki T. Jalkanen ◽

Tapio A. Kuoppala ◽

Arto O. Leminen ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(19)30178-0 ◽

2019 ◽

Vol 20 (6) ◽

pp. 862-876 ◽

Author(s):

Ignace Vergote ◽

Giovanni Scambia ◽

David M O'Malley ◽

Ben Van Calster ◽

Sang-Yoon Park ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Line Treatment ◽

Phase 3 ◽

Double Blind ◽

First Line Treatment

Download Full-text

Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials

Journal of Chemotherapy ◽

10.1179/1120009x12z.0000000002 ◽

2012 ◽

Vol 24 (2) ◽

pp. 67-73 ◽

Author(s):

Hui Zhang ◽

Lin Jia ◽

Yintao Xu ◽

Xun Clare Zhou ◽

Beihua Kong ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Advanced Ovarian Cancer ◽

Controlled Trials ◽

Line Treatment ◽

Randomized Controlled ◽

First Line Treatment

Download Full-text

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Yearbook of Oncology ◽

10.1016/s1040-1741(08)70320-8 ◽

2007 ◽

Vol 2007 ◽

pp. 70-71

Author(s):

J.T. Thigpen

Keyword(s):

Ovarian Cancer ◽

Gynecologic Cancer ◽

Advanced Ovarian Cancer ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Intergroup Trial ◽

First Line Treatment

Download Full-text